Anthera Pharmaceuticals� $ANTH fell sharply amid heavy trading volume in response to its announcement that CHABLIS-SC1, evaluating blisibimod for the treatment of patients with active systemic lupus erythematosus (SLE) failed to achieve its primary endpoint.